Related Experiment Video

Updated: Nov 14, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.2K

EGFR-mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib

Reina Hara1,2, Masaki Kanazu1, Ami Iwai1,3

  • 1Department of Thoracic Oncology, Osaka Toneyama Medical Center, Osaka, Japan.

Thoracic Cancer
|March 8, 2021
PubMed

Insights

A rare case of EGFR-mutant lung adenocarcinoma with antisynthetase syndrome (ASS) and interstitial lung disease (ILD) was treated with osimertinib. This suggests osimertinib may be a viable option for lung cancer patients with paraneoplastic ILD.

Area of Science:

  • Oncology
  • Rheumatology
  • Pulmonology

Background:

  • Epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma is a significant malignancy.
  • Antisynthetase syndrome (ASS) is an autoimmune disorder often associated with interstitial lung disease (ILD).
  • Paraneoplastic syndromes can complicate cancer treatment and patient outcomes.

Observation:

  • A 66-year-old male patient presented with respiratory failure and bilateral pulmonary opacities.
  • The patient was diagnosed with EGFR-mutant lung adenocarcinoma and ASS with ILD, indicative of a paraneoplastic syndrome.
  • Initial treatment involved steroid pulse therapy.

Findings:

  • Osimertinib was administered for the lung adenocarcinoma following steroid therapy.
  • The patient's interstitial lung disease (ILD) did not exacerbate during osimertinib treatment.
  • This case demonstrates successful management of lung cancer in the presence of ASS-related ILD.

Implications:

  • Osimertinib may represent a potential therapeutic option for patients with EGFR-mutant lung cancer and co-existing paraneoplastic ILD.
  • This finding broadens treatment considerations for complex cases involving both malignancy and autoimmune lung disease.
  • Further research is warranted to explore the efficacy and safety of targeted therapies in such multifaceted presentations.
Keywords:
aminoacyl transfer RNA synthetaseinterstitial lung diseaselung cancer

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.4K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
281
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K